Acute myeloid leukemia (AML) is the most common leukemia.
For the past 56 years, tremendous development and improvement have taken place. In particular, discoveries of gene mutations of leukemic cells lead to development of specific inhibitors targeting the mutated genes. It also was found that the molecular genetics of leukemia are associated with prognosis. Patient who belong to poor prognostic group are treated with more intense therapy such as allogeneic hematopoietic stem cell transplantation while favorable group can be managed without stem cell transplantation. I present the most updated and comprehensive review in diagnosis and treatment of AML